Teleflex Inc Stock Price, News & Analysis

Teleflex (NYSE: TFX) launches two major initiatives during Men's Health Month to raise awareness about prostate health issues. The company introduced the Prostate Monster ad campaign highlighting benign prostatic hyperplasia (BPH) symptoms and the Prostate Education Express mobile center for physician training and community education. The UroLift System, their leading BPH treatment, has treated over 500,000 men worldwide. The mobile education center will tour major U.S. cities, providing training on both the UroLift System and Barrigel rectal spacer. The Barrigel spacer, used before prostate cancer radiation therapy, has shown 98.5% success in reducing rectal radiation exposure by at least 25%, with average reductions of 85%. The initiatives aim to educate about BPH, which affects 14.1 million treatment-seeking men annually in the US, and promote prostate health awareness.

Teleflex (NYSE: TFX) has released its 2024 Global Impact Report, detailing the company's Corporate Social Responsibility (CSR) achievements and future objectives. The report adheres to GRI, SASB, and TCFD standards, focusing on four key pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.

Key highlights include: completion of a double materiality assessment aligned with E.U. Corporate Sustainability Reporting Directive, signing the World Economic Forum Zero Health Gaps Pledge for equitable healthcare access, submission of CDP Climate Questionnaire tracking greenhouse gas emissions since 2019, and maintaining ISO 14001 certification across 6 facilities.

Teleflex (NYSE: TFX) presented new clinical data at the 2025 AUA Annual Meeting showcasing the superiority of their UroLift™ System for BPH treatment. Two key randomized controlled trials demonstrated that UroLift™ outperformed both Rezūm and tamsulosin treatments. The studies showed patients treated with UroLift™ experienced higher satisfaction rates, shorter catheterization times, and better sexual function outcomes. Notably, 70% of patients in the medication arm switched to UroLift™ treatment. Real-world data from the AQUA BPH database confirmed UroLift's superior symptom improvement at three months compared to drug treatments. Additionally, research validated the safety of Teleflex's stabilized Hyaluronic Acid (sHA) rectal spacer, showing low risk of complications in prostate cancer treatment.

A new retrospective study published in Obesity Surgery highlights significant benefits of Teleflex's (NYSE: TFX) Titan SGS™ Stapler in sleeve gastrectomy procedures. The study of 257 patients showed that at one-year post-procedure, patients treated with the Titan SGS™ Stapler experienced significantly lower rates of GERD (7.1% vs 26.4%) and de novo GERD (1.8% vs 10.9%) compared to multi-fire staplers. The Titan SGS™ Stapler, being the first and only single-fire surgical stapler specifically designed for sleeve gastrectomy, features a 23cm continuous staple line that creates consistent tubular sleeve anatomy. The study demonstrated that GERD resolution was higher in the Titan SGS™ cohort (25% vs 10.9%), while maintaining equivalent weight loss outcomes (approximately 22%) compared to traditional multi-fire staplers.

Teleflex (NYSE:TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be paid on June 16, 2025, to shareholders who are on record as of the close of business on May 20, 2025. This dividend declaration demonstrates the company's commitment to returning value to shareholders through regular cash distributions.

Teleflex (NYSE: TFX) reported its Q1 2025 financial results and updated full-year guidance. Q1 revenues were $700.7 million, down 5.0% year-over-year, with adjusted constant currency decline of 3.8%. The company reported GAAP EPS of $2.07 and adjusted EPS of $2.91, compared to $0.33 and $3.21 respectively in the prior year. For 2025 guidance, Teleflex raised GAAP revenue growth outlook to 1.28%-2.28% but lowered adjusted EPS guidance to $13.20-$13.60, primarily due to a $55 million impact from tariffs. The company completed a $300 million accelerated share repurchase on April 9, 2025. Notably, Teleflex is proceeding with its previously announced separation into two independent public companies and is actively exploring potential sale options for NewCo following significant third-party interest.

Teleflex (NYSE: TFX) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. The company's management will deliver a presentation at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. Pacific Time.

Investors and interested parties can access a live audio webcast of the presentation through the investor section of Teleflex's website at teleflex.com. This healthcare conference appearance represents an opportunity for Teleflex to engage with industry stakeholders and share company updates.

Teleflex has received FDA 510(k) clearance for expanded indications of its QuikClot Control+™ Hemostatic Device, now approved for all grades of internal and external bleeding. This expansion significantly broadens the device's applications beyond its previous indications for specific surgical procedures and bleeding types.

The clearance was supported by real-world evidence from a study of 603 emergency, trauma, and surgical patients across multiple U.S. sites. The expanded indication is expected to add over $150 million to Teleflex's serviceable addressable market in the United States.

The device can now be used for temporary control of external and internal bleeding ranging from mild to life-threatening cases. Already commercialized in the European Union in 2024, this development allows Teleflex to target additional procedures in trauma, general surgery, gynecologic surgery, and orthopedic surgery, potentially improving clinical and economic outcomes.

Teleflex (NYSE:TFX) has announced multiple clinical studies and educational sessions to be presented at the 2025 American Urological Association Annual Meeting in Las Vegas from April 26-29, 2025.

The presentations will focus on clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing for prostate cancer radiation treatment. Key studies include the CLEAR Randomized Controlled Trial comparing UroLift™ PUL versus Rezum WVTT, the IMPACT trial evaluating UroLift™ PUL versus medication, and research on the safety of stabilized hyaluronic acid as a rectal spacer.

The company will host several educational events, including a Semi-Live Barrigel Case Review, an APP educational breakfast on efficient urology practice, and a Prostate Health Symposium at Allegiant Stadium. Daily presentations will also take place at Teleflex booth 1401, featuring discussions on both the Barrigel™ rectal spacer and UroLift™ System.